Search research articles
Contact Us
Filters
Showing results (151-160 of 198) with videos related to
Page
of 20
Sort By:
Journal for Immunotherapy of Cancer
|
December 30, 2016
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
Douglas G McNeel, Neil H Bander, Tomasz M Beer, et al.
Cell
|
June 5, 2020
Intratumoral CD4<sup>+</sup> T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer
David Y Oh, Serena S Kwek, Siddharth S Raju, et al.
BJU International
|
April 2, 2020
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma
Sumanta K Pal, David F McDermott, Michael B Atkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2009
A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies
Amy J Chien, Julie A Illi, Andrew H Ko, et al.
Frontiers in Oncology
|
April 24, 2023
Somatic alterations of <i>TP53</i> and <i>MDM2</i> associated with response to enfortumab vedotin in patients with advanced urothelial cancer
Tanya Jindal, Xiaolin Zhu, Rohit Bose, et al.
European Urology
|
August 22, 2024
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial
Ronald de Wit, David J Vaughn, Yves Fradet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2018
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer
David J Vaughn, Joaquim Bellmunt, Yves Fradet, et al.
Investigational New Drugs
|
March 3, 2026
Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534
Matthew R Chrostek, James Robinson, Rajesh Krishnan, et al.
Clinical Genitourinary Cancer
|
June 29, 2017
High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer
Terence W Friedlander, Julie N Graff, Kreshnik Zejnullahu, et al.
Journal for Immunotherapy of Cancer
|
June 5, 2021
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release
Kevin Dang, Giulia Castello, Starlynn C Clarke, et al.
Page
of 20
Search research articles
Search
Showing results (151-160 of 198) with videos related to
Sort By:
Page
of 20
Journal for Immunotherapy of Cancer
|
December 30, 2016
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
Douglas G McNeel, Neil H Bander, Tomasz M Beer, et al.
Cell
|
June 5, 2020
Intratumoral CD4<sup>+</sup> T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer
David Y Oh, Serena S Kwek, Siddharth S Raju, et al.
BJU International
|
April 2, 2020
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma
Sumanta K Pal, David F McDermott, Michael B Atkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2009
A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies
Amy J Chien, Julie A Illi, Andrew H Ko, et al.
Frontiers in Oncology
|
April 24, 2023
Somatic alterations of <i>TP53</i> and <i>MDM2</i> associated with response to enfortumab vedotin in patients with advanced urothelial cancer
Tanya Jindal, Xiaolin Zhu, Rohit Bose, et al.
European Urology
|
August 22, 2024
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial
Ronald de Wit, David J Vaughn, Yves Fradet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2018
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer
David J Vaughn, Joaquim Bellmunt, Yves Fradet, et al.
Investigational New Drugs
|
March 3, 2026
Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534
Matthew R Chrostek, James Robinson, Rajesh Krishnan, et al.
Clinical Genitourinary Cancer
|
June 29, 2017
High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer
Terence W Friedlander, Julie N Graff, Kreshnik Zejnullahu, et al.
Journal for Immunotherapy of Cancer
|
June 5, 2021
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release
Kevin Dang, Giulia Castello, Starlynn C Clarke, et al.
Page
of 20